UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $482,000 Stock Holdings in Iradimed Corporation (NASDAQ:IRMD)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its stake in Iradimed Corporation (NASDAQ:IRMD) by 20.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,585 shares of the medical equipment provider’s stock after selling 2,446 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.08% of Iradimed worth $482,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the company. Shaker Investments LLC OH grew its stake in Iradimed by 1.7% during the second quarter. Shaker Investments LLC OH now owns 20,605 shares of the medical equipment provider’s stock worth $905,000 after buying an additional 347 shares during the last quarter. ClariVest Asset Management LLC increased its stake in shares of Iradimed by 2.9% in the second quarter. ClariVest Asset Management LLC now owns 17,666 shares of the medical equipment provider’s stock valued at $776,000 after buying an additional 494 shares in the last quarter. Huntington National Bank raised its holdings in shares of Iradimed by 51.3% in the third quarter. Huntington National Bank now owns 1,487 shares of the medical equipment provider’s stock valued at $75,000 after buying an additional 504 shares during the last quarter. Cim LLC grew its holdings in Iradimed by 5.9% during the 2nd quarter. Cim LLC now owns 10,089 shares of the medical equipment provider’s stock worth $464,000 after acquiring an additional 561 shares during the last quarter. Finally, Kings Path Partners LLC increased its position in Iradimed by 2.3% in the 3rd quarter. Kings Path Partners LLC now owns 24,570 shares of the medical equipment provider’s stock valued at $1,236,000 after acquiring an additional 562 shares in the last quarter. Institutional investors own 92.34% of the company’s stock.

Iradimed Trading Up 2.4 %

Shares of NASDAQ IRMD opened at $54.65 on Friday. Iradimed Corporation has a 1-year low of $40.18 and a 1-year high of $57.95. The company has a 50-day moving average of $52.97 and a two-hundred day moving average of $48.30. The company has a market cap of $692.58 million, a PE ratio of 37.43 and a beta of 0.82.

Iradimed Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, November 25th. Stockholders of record on Friday, November 15th were given a dividend of $0.15 per share. The ex-dividend date was Friday, November 15th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 1.10%. Iradimed’s payout ratio is currently 41.10%.

Insiders Place Their Bets

In related news, CFO John Glenn sold 2,500 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $54.18, for a total transaction of $135,450.00. Following the completion of the transaction, the chief financial officer now owns 4,383 shares in the company, valued at approximately $237,470.94. The trade was a 36.32 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 37.10% of the company’s stock.

Iradimed Profile

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.